Literature DB >> 33867788

Acute exacerbations of interstitial lung disease: what is the best treatment?

Keith C Meyer1.   

Abstract

Entities:  

Year:  2021        PMID： 33867788      PMCID： PMC8050625          DOI： 10.36141/svdld.v38i1.11520

Source DB:  PubMed          Journal:  Sarcoidosis Vasc Diffuse Lung Dis        ISSN： 1124-0490            Impact factor:   0.670


× No keyword cloud information.
  13 in total

Review 1.  American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS).

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2000-02       Impact factor: 21.405

Review 2.  Acute exacerbations of progressive-fibrosing interstitial lung diseases.

Authors:  Martin Kolb; Benjamin Bondue; Alberto Pesci; Yasunari Miyazaki; Jin Woo Song; Nitin Y Bhatt; John T Huggins; Justin M Oldham; Maria L Padilla; Jesse Roman; Shane Shapera
Journal:  Eur Respir Rev       Date:  2018-12-21

3.  Cyclophosphamide in the treatment of idiopathic pulmonary fibrosis: a prospective study in patients who failed to respond to corticosteroids.

Authors:  D A Zisman; J P Lynch; G B Toews; E A Kazerooni; A Flint; F J Martinez
Journal:  Chest       Date:  2000-06       Impact factor: 9.410

4.  Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.

Authors:  Ganesh Raghu; Kevin J Anstrom; Talmadge E King; Joseph A Lasky; Fernando J Martinez
Journal:  N Engl J Med       Date:  2012-05-20       Impact factor: 91.245

Review 5.  Acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF): an overview of current and future therapeutic strategies.

Authors:  Davide Biondini; Elisabetta Balestro; Nicola Sverzellati; Elisabetta Cocconcelli; Nicol Bernardinello; Christopher J Ryerson; Paolo Spagnolo
Journal:  Expert Rev Respir Med       Date:  2020-02-03       Impact factor: 3.772

Review 6.  Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report.

Authors:  Harold R Collard; Christopher J Ryerson; Tamera J Corte; Gisli Jenkins; Yasuhiro Kondoh; David J Lederer; Joyce S Lee; Toby M Maher; Athol U Wells; Katerina M Antoniou; Juergen Behr; Kevin K Brown; Vincent Cottin; Kevin R Flaherty; Junya Fukuoka; David M Hansell; Takeshi Johkoh; Naftali Kaminski; Dong Soon Kim; Martin Kolb; David A Lynch; Jeffrey L Myers; Ganesh Raghu; Luca Richeldi; Hiroyuki Taniguchi; Fernando J Martinez
Journal:  Am J Respir Crit Care Med       Date:  2016-08-01       Impact factor: 21.405

7.  Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.

Authors:  Athol U Wells; Kevin R Flaherty; Kevin K Brown; Yoshikazu Inoue; Anand Devaraj; Luca Richeldi; Teng Moua; Bruno Crestani; Wim A Wuyts; Susanne Stowasser; Manuel Quaresma; Rainer-Georg Goeldner; Rozsa Schlenker-Herceg; Martin Kolb
Journal:  Lancet Respir Med       Date:  2020-03-05       Impact factor: 30.700

8.  Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  Robert P Baughman; Keith C Meyer; Ian Nathanson; Luis Angel; Sangeeta M Bhorade; Kevin M Chan; Daniel Culver; Christopher G Harrod; Mary S Hayney; Kristen B Highland; Andrew H Limper; Herbert Patrick; Charlie Strange; Timothy Whelan
Journal:  Chest       Date:  2012-11       Impact factor: 9.410

9.  Study protocol: exploring the efficacy of cyclophosphamide added to corticosteroids for treating acute exacerbation of idiopathic pulmonary fibrosis; a randomized double-blind, placebo-controlled, multi-center phase III trial (EXAFIP).

Authors:  Jean-Marc Naccache; Melissa Montil; Jacques Cadranel; Marine Cachanado; Vincent Cottin; Bruno Crestani; Dominique Valeyre; Benoit Wallaert; Tabassome Simon; Hilario Nunes
Journal:  BMC Pulm Med       Date:  2019-04-11       Impact factor: 3.317

10.  Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.

Authors:  Ganesh Raghu; Martine Remy-Jardin; Jeffrey L Myers; Luca Richeldi; Christopher J Ryerson; David J Lederer; Juergen Behr; Vincent Cottin; Sonye K Danoff; Ferran Morell; Kevin R Flaherty; Athol Wells; Fernando J Martinez; Arata Azuma; Thomas J Bice; Demosthenes Bouros; Kevin K Brown; Harold R Collard; Abhijit Duggal; Liam Galvin; Yoshikazu Inoue; R Gisli Jenkins; Takeshi Johkoh; Ella A Kazerooni; Masanori Kitaichi; Shandra L Knight; George Mansour; Andrew G Nicholson; Sudhakar N J Pipavath; Ivette Buendía-Roldán; Moisés Selman; William D Travis; Simon Walsh; Kevin C Wilson
Journal:  Am J Respir Crit Care Med       Date:  2018-09-01       Impact factor: 21.405
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.